Jefferies reiterates Summit Therapeutics stock rating after FDA setback
Jefferies reiterated a Buy rating and $30 price target for Summit Therapeutics (SMMT) after the FDA issued a Complete Response Letter for its lung cancer treatment. The stock fell 13% last week. Jefferies sees limited downside and expects HARMONi-3 data as a key catalyst. Other analysts also maintain Buy ratings with higher targets. Summit reported Q3 2026 results and filed for common stock issuance.
How this was made
The 30-second read
Why it matters
The CRL is a fresh regulatory setback that may trigger short‑term selling pressure, but analysts note limited downside and a future catalyst in HARMONi‑3 data.
Market read
Regulatory news for a small‑cap biotech; immediate impact on SMMT price with potential sector‑wide caution.
What to watch
Upcoming HARMONi-3 data later in 2026 could re‑ignite upside if results are strong.
Background
Summit Therapeutics (NASDAQ:SMMT) is a clinical‑stage biotech developing ivonescimab for various cancers. The FDA issued a Complete Response Letter for its second‑line EGFR NSCLC trial.
Ticker impact
Jefferies reiterated a Buy rating and $30 price target after Summit Therapeutics received an FDA Complete Response Letter for its ivonescimab trial.
likely downside as investors price in the regulatory setback
The CRL is a fresh, material regulatory decision that directly affects the company's key trial and future revenue prospects.
Market effects
Biotech sector may see broader caution on FDA trial outcomes.
US biotech stocks could face short-term pressure.
Limited to companies with similar FDA trial pipelines.
Counterpoint
Jefferies still sees limited downside and maintains a Buy rating, suggesting potential rebound if later data are positive.
Key entities
- companySummit Therapeutics plc
Biotech firm developing ivonescimab.
- analystJefferies
Equity research firm reiterating a Buy rating.
